Geoffrey M. Parker
Independent DirectorMr. Geoffrey M. Parker, also known as Geoff, had been the Chief Operating Officer of Tricida, Inc. since February 16, 2021. He served as Executive Vice President and Chief Financial Officer of Allogene Therapeutics, Inc. since October 2023 until November 6, 2026. He had been the Chief Financial Officer of Tricida, Inc. since April 2017 and served as its Executive Vice President since February 2020. He was Senior Vice President of Tricida, Inc. since April 2017 until February 2020. He has been Consultant of Anacor Pharmaceuticals, Inc. from June 2015 to November 2015. He served as the Chief Financial Officer of Anacor Pharmaceuticals Inc. from September 2010 to June 1, 2015 and served as its Principal Accounting Officer and Executive Vice President from May 2014 to June 1, 2015. He served as an Advisor to the Chief Executive Officer of Anacor Pharmaceuticals, Inc. since December 2009 and served as its Senior Vice President from September 2010 to May 2014. He served as Chief Business Officer of InteKrin Therapeutics, Inc. from July 2009 to July 2010. Mr. Parker joined Goldman Sachs in 1986 in the Corporate Finance department in New York. From April 1, 1997 to April 2009, he served as Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc. and led Goldman Sachs' West Region Healthcare Investment Banking practice from April 1997 to April 2009 during which time he advised many of the biotechnology industry's leading companies such as Genentech, Amgen, Gilead and Amylin. He served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, he served as Vice President at Feibusch & Co. From 1997 to 2009, he led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. His advisory work ranged from capital market activities to strategic mergers and acquisitions. He has extensive healthcare investment banking experience, broad knowledge of financial markets and expertise as a strategic advisor to healthcare, diagnostic and other life sciences companies. He has finance and executive leadership experience. He had significant transactional and advisory experience working with life sciences companies in various capacities at Goldman Sachs. He served as a Director of Genomic Health, Inc. from June 21, 2016 to November 8, 2019. He served as a Director of Genoptix, Inc. since June 1, 2010. He serves as Independent Director of Perrigo Company plc since November 7, 2016. He was Director at ChemoCentryx, Inc. since December 2009 until October 20, 2022. He has been an Independent Director of Better Therapeutics, Inc. since October 2021. He was also a member of the board of directors of Sunesis Pharmaceuticals, Inc. from March 2016 until December 2017. He holds AB degree in Economics and Engineering Science at Dartmouth College and an MBA from Stanford University.
Positions
- Company NamePerrigo Company plcStock CodePRGOPositionIndependent DirectorColleagues
- AAAlbert Ange ManzoneInterim President, Interim CEO & Director
- ODOrlando Dwayne AshfordIndependent Chairman of the Board
- EGEduardo Guarita BezerraExecutive VP & CFO
- ALAbbie LennoxEVP & Chief Scientific Officer
- CACharles AtkinsonExecutive VP, General Counsel & Secretary
- RKRoberto KhouryExecutive VP & Chief Commercial Officer
- DMDonal M. O'ConnorIndependent Director
- BABradley A. AlfordIndependent Director
- Company NameBetter Therapeutics, Inc.Stock CodeBTTXPositionIndependent DirectorColleagues
- DPDavid P. PerryCo-Founder & Executive Chairman
- FLFrank L. KarbeInterim CFO
- MAMark A. BermanChief Medical Officer
- KWKristin WynholdsChief Product Officer
- ACAndres CamachoSenior VP of Technology & Head of Engineering
- AJAndrew J. ArmaninoIndependent Director
- GMGeoffrey M. ParkerIndependent Director
- RHRichard H. CarmonaIndependent Director
- EGElder GrangerIndependent Director
